These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1065 related articles for article (PubMed ID: 20362709)

  • 1. Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study.
    Bhardwaj A; Rehman SU; Mohammed A; Baggish AL; Moore SA; Januzzi JL
    Am Heart J; 2010 Apr; 159(4):532-538.e1. PubMed ID: 20362709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
    von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
    J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life and chronic heart failure therapy guided by natriuretic peptides: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study.
    Bhardwaj A; Rehman SU; Mohammed AA; Gaggin HK; Barajas L; Barajas J; Moore SA; Sullivan D; Januzzi JL
    Am Heart J; 2012 Nov; 164(5):793-799.e1. PubMed ID: 23137512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
    Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
    Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial).
    Masson S; Latini R; Anand IS; Barlera S; Angelici L; Vago T; Tognoni G; Cohn JN;
    J Am Coll Cardiol; 2008 Sep; 52(12):997-1003. PubMed ID: 18786480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial.
    Lainchbury JG; Troughton RW; Strangman KM; Frampton CM; Pilbrow A; Yandle TG; Hamid AK; Nicholls MG; Richards AM
    J Am Coll Cardiol; 2009 Dec; 55(1):53-60. PubMed ID: 20117364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of the plasma brain natriuretic peptide in differentiating patients with congestive heart failure from other diseases.
    Sirithunyanont C; Leowattana W; Sukumalchantra Y; Chaisupamonkollarp S; Watanawaroon S; Chivatanaporn B; Bhuripanyo K; Mahanonda N
    J Med Assoc Thai; 2003 May; 86 Suppl 1():S87-95. PubMed ID: 12866774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-terminal pro-brain natriuretic peptide testing in the emergency department: beneficial effects on hospitalization, costs, and outcome.
    Rutten JH; Steyerberg EW; Boomsma F; van Saase JL; Deckers JW; Hoogsteden HC; Lindemans J; van den Meiracker AH
    Am Heart J; 2008 Jul; 156(1):71-7. PubMed ID: 18585499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outpatient monitoring and treatment of chronic heart failure guided by amino-terminal pro-B-type natriuretic peptide measurement.
    Troughton RW; Richards AM
    Am J Cardiol; 2008 Feb; 101(3A):72-5. PubMed ID: 18243863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction.
    Grewal J; McKelvie RS; Persson H; Tait P; Carlsson J; Swedberg K; Ostergren J; Lonn E
    Am J Cardiol; 2008 Sep; 102(6):733-7. PubMed ID: 18773998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative value of BNP and NT-proBNP in diagnosis of heart failure.
    Fonseca C; Sarmento PM; Minez A; Gonçalves E; Covas R; Dias AR; Pina MJ; Ceia F
    Rev Port Cardiol; 2004; 23(7-8):979-91. PubMed ID: 15478324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure).
    Cleland JG; McMurray JJ; Kjekshus J; Cornel JH; Dunselman P; Fonseca C; Hjalmarson A; Korewicki J; Lindberg M; Ranjith N; van Veldhuisen DJ; Waagstein F; Wedel H; Wikstrand J;
    J Am Coll Cardiol; 2009 Nov; 54(20):1850-9. PubMed ID: 19892235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heart failure outcomes and benefits of NT-proBNP-guided management in the elderly: results from the prospective, randomized ProBNP outpatient tailored chronic heart failure therapy (PROTECT) study.
    Gaggin HK; Mohammed AA; Bhardwaj A; Rehman SU; Gregory SA; Weiner RB; Baggish AL; Moore SA; Semigran MJ; Januzzi JL
    J Card Fail; 2012 Aug; 18(8):626-34. PubMed ID: 22858078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-terminal pro-brain natriuretic peptide, kidney disease and outcome in patients with chronic heart failure.
    Bruch C; Reinecke H; Stypmann J; Rothenburger M; Schmid C; Breithardt G; Wichter T; Gradaus R
    J Heart Lung Transplant; 2006 Sep; 25(9):1135-41. PubMed ID: 16962477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease.
    Neuhold S; Huelsmann M; Strunk G; Stoiser B; Struck J; Morgenthaler NG; Bergmann A; Moertl D; Berger R; Pacher R
    J Am Coll Cardiol; 2008 Jul; 52(4):266-72. PubMed ID: 18634981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study.
    Berger R; Moertl D; Peter S; Ahmadi R; Huelsmann M; Yamuti S; Wagner B; Pacher R
    J Am Coll Cardiol; 2010 Feb; 55(7):645-53. PubMed ID: 20170790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutoff values of NT-proBNP for the prediction of low functional capacity, decreased ejection fraction and cardiovascular events in patients with heart failure.
    Koç M; Bozkurt A; Yildiray-Sahin D; Unal I; Acartürk E
    Cardiol J; 2009; 16(1):43-9. PubMed ID: 19130415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amino-terminal pro-B-type natriuretic peptide testing for inpatient monitoring and treatment guidance of acute destabilized heart failure.
    Bettencourt P; Januzzi JL
    Am J Cardiol; 2008 Feb; 101(3A):67-71. PubMed ID: 18243862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients.
    Bettencourt P; Azevedo A; Pimenta J; Friões F; Ferreira S; Ferreira A
    Circulation; 2004 Oct; 110(15):2168-74. PubMed ID: 15451800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population.
    Lam CS; Burnett JC; Costello-Boerrigter L; Rodeheffer RJ; Redfield MM
    J Am Coll Cardiol; 2007 Mar; 49(11):1193-202. PubMed ID: 17367664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.